Antiplatelet treatment in essential hypertension: where do we stand?

Current Hypertension Reports
Eugenia GkaliagkousiStella Douma

Abstract

Antiplatelet agents represent a cornerstone in the management of patients at increased cardiovascular risk. Essential hypertension is considered a major public health problem leading to increased cardiovascular morbidity and mortality. The majority of patients with essential hypertension exhibit also additional cardiovascular risk factors and present with increased platelet activation. Despite recent innovations in the field of antiplatelet treatment and the introduction of novel agents, the role of antiplatelet treatment in patients with essential hypertension remains understudied. This review aims to shed light on novel experimental and clinical data in the evolving field of antiplatelet treatment in essential hypertension. In particular, recent data regarding aspirin, clopidogrel, novel P2Y12 inhibitors, and other agents with potential antiplatelet effects are critically reviewed.

References

Jul 21, 1998·The New England Journal of Medicine·T W Meade
Sep 12, 2007·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Koji YamadaYasuhiro Hasegawa
Jan 19, 2008·BMJ : British Medical Journal·George KrasopoulosMichael R Buchanan
Feb 14, 2008·European Journal of Clinical Nutrition·C L Fischer WalkerR E Black
Apr 19, 2008·Clinical Chemistry·Brad S KaronAllan S Jaffe
Nov 15, 2008·Journal of the American College of Cardiology·Jolanta M Siller-MatulaBernd Jilma
Aug 19, 2009·Heart·Thomas GremmelChristoph W Kopp
Jan 23, 2010·American Journal of Hypertension·Eugenia GkaliagkousiAlbert Ferro
Oct 12, 2010·The New England Journal of Medicine·Deepak L BhattUNKNOWN COGENT Investigators
Oct 23, 2010·Stroke; a Journal of Cerebral Circulation·Karen L FurieUNKNOWN American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisci
Feb 8, 2011·Lancet·Goodarz DanaeiUNKNOWN Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Pressure)
May 31, 2011·Thrombosis Research·Thomas GremmelChristoph W Kopp
Nov 30, 2011·Journal of Cardiovascular Pharmacology and Therapeutics·John P MuradFadi T Khasawneh
Dec 14, 2011·The Cochrane Database of Systematic Reviews·Gregory Yh LipGirish Dwivedi
Mar 1, 2012·Thrombosis and Haemostasis·Paul C Armstrong, Karlheinz Peter
Aug 31, 2012·The New England Journal of Medicine·UNKNOWN SPS3 InvestigatorsLesly A Pearce
Nov 6, 2012·Journal of Clinical Pharmacy and Therapeutics·M M SalamaL A ElSafady
Dec 19, 2012·Circulation·Patrick T O'GaraUNKNOWN American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Feb 22, 2013·European Heart Journal·Stefan AgewallUNKNOWN ESC Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis
Mar 16, 2013·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Ibrahim Faruk AkturkIlker Murat Caglar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Related Papers

Current Opinion in Hematology
Galia Spectre, David Varon
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Joshua Sullivan, Naseem Amarshi
© 2021 Meta ULC. All rights reserved